{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088700","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.119046+00:00","generated_at":"2026-05-19T00:31:28.894024+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA alignment opens third dosing cohort for Perspective's 212Pb-VMT-α-NET NET trial at 6 mCi (20% higher)","bullets":["FDA opened Cohort 3 at 6 mCi (20% higher than Cohort 2) per dose for patients weighing >60 kg.","No DLTs observed among 42 patients treated; no grade ≥4 AEs; anti-tumor activity in 4 of 7 Cohort 2 DLT-evaluable patients.","Dosimetry sub-study using [203Pb]VMT-α-NET presented at SNMMI 2025 shows feasibility and tolerable absorbed doses.","Company on track to submit further clinical updates in 2H 2025, including longer safety and anti-tumor activity data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088700","json":"https://secwatch.observer/filing/0000950170-25-088700.json","markdown":"https://secwatch.observer/filing/0000950170-25-088700.md","text":"https://secwatch.observer/filing/0000950170-25-088700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025088700/0000950170-25-088700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025088700/catx-20250621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T00:31:28.894024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}